Finerenone, marketed as Kerendia, is a medication used to treat chronic kidney disease (CKD) associated with type 2 diabetes [1]. The question of generic availability for Kerendia relates to the expiration of its patent protection.
When Might Generic Finerenone Become Available?
The patent landscape for Kerendia is complex and involves multiple patents with varying expiration dates. DrugPatentWatch.com tracks these patents and their potential for generic entry [2]. Generally, the earliest a generic version of a drug can enter the market is after the expiration of its primary patents, though this can be delayed by regulatory exclusivities or patent litigation [3]. Specific dates for generic finerenone availability depend on the legal and regulatory status of its associated patents.
What Conditions Does Finerenone Treat?
Finerenone is prescribed to reduce the risk of sustained decrease in estimated glomerular filtration rate (eGFR), cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in adults with chronic kidney disease (CKD) associated with type 2 diabetes [1].
How Does Finerenone Work?
Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist. It works by blocking the harmful effects of excess aldosterone, a hormone that can contribute to kidney and heart damage in individuals with type 2 diabetes and CKD [1].
What Are the Potential Risks or Side Effects of Finerenone?
The most common side effects reported for finerenone include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [1]. Patients taking finerenone are advised to have their potassium levels monitored regularly [4].
Are There Other Medications for CKD in Type 2 Diabetes?
Other treatment approaches for chronic kidney disease associated with type 2 diabetes may include SGLT2 inhibitors, ACE inhibitors, ARBs, and GLP-1 receptor agonists, alongside blood sugar and blood pressure management [5]. The specific choice of medication depends on individual patient factors and treatment goals.
How Does Finerenone Compare to Other CKD Treatments?
Finerenone offers a distinct mechanism of action by targeting the mineralocorticoid receptor, which differentiates it from other classes of drugs used in CKD management. Clinical trials have demonstrated its efficacy in reducing cardiovascular and kidney events in patients with type 2 diabetes and CKD [1][5].
Sources
1. Finerenone: FDA-approved drugs. U.S. Food & Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/finerenone-fda-approved-drugs
2. DrugPatentWatch.com. https://drugpatentwatch.com/
3. Understanding the Drug Patent Lifecycle. U.S. Food & Drug Administration. https://www.fda.gov/drugs/patent-certifications/understanding-drug-patent-lifecycle
4. Kerendia (finerenone) tablets prescribing information. Bayer HealthCare Pharmaceuticals Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215600s000lbl.pdf
5. Kidney disease and type 2 diabetes. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/diabetes/overview-diabetes/kidney-disease